It has been reported that the expression of PD-L1 on CTCs from patients can be evaluated and potentially used as a predictor for the efficacy of chemotherapy, radiotherapy, and PD-1 blockade therapy for several kinds of solid tumors, including NSCLC [20,21,22,23,24,25]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.